Previous 10 | Next 10 |
home / stock / vrca / vrca articles
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology thera...
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigatin...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology thera...
NEW YORK, April 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigat...
WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company...
WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology ther...
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology ther...
Lawsuit alleges false and misleading advertising and promotion of unapproved cantharidin-containing drugs by Dormer Laboratories in violation of f...
News, Short Squeeze, Breakout and More Instantly...
Verrica Pharmaceuticals Inc. Company Name:
VRCA Stock Symbol:
NASDAQ Market:
Verrica Pharmaceuticals Inc. Website:
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 202...
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Pr...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a min...